1508-65-2 Usage
Chemical Properties
White to Off-White Solid
Originator
Ditropan, Marion , US ,1975
Uses
Different sources of media describe the Uses of 1508-65-2 differently. You can refer to the following data:
1. An inhibitor of proliferation and supresses gene expression in bladder smooth muscle cells
2. anticholinergic
3. An antagonist of M1, M2, & M3 muscarinic acetylcholine receptors
Manufacturing Process
A mixture of 394.2 grams of methyl phenylcyclohexylglycolate and 293.1 grams of 4-diethylamino-2-butynyl acetate was dissolved with warming in 2.6 liters of n-heptane. The solution was heated with stirring to a temperature of 60° to 70°C and 8.0 grams of sodium methoxide were added. The temperature of the mixture was then raised until the solvent began to distill. Distillation was continued at a gradual rate and aliquots of the distillate were successively collected and analyzed for the presence of methyl acetate by measurement of the refractive index. The reaction was completed when methyl acetate no longer distilled, and the refractive index observed was that of pure heptane (nD26 = 1.3855). About 3? hours were required for the reaction to be completed.
The reaction mixture was then allowed to cool to room temperature, washed with water, and extracted with four 165 ml portions of 2 N hydrochloric acid. The aqueous extracts were combined and stirred at room temperature to permit crystallization of the hydrochloride salt of the desired product. Crystallization was completed by cooling the slurry in an ice bath, and the product was collected by filtration, pressed dry, and recrystallized from 750 ml of water. Yield of pure crystalline material, 323 grams.
Brand name
Ditropan (ALZA).
Therapeutic Function
Spasmolytic
Biological Activity
oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.
Biochem/physiol Actions
Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.
Clinical Use
Urinary frequency, urgency and incontinence
Neurogenic bladder instability and nocturnal
enuresis
Safety Profile
Poison by ingestion, intravenous, and intraperitoneal routes. An experimental teratogen. Experimental reproductive effects. An eye irritant. Human systemic effects: coma, mydriasis, rate changes. An anticholinergic agent. When heated to decomposition it e
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic
side effects with disopyramide.
Other antimuscarinic agents: increased
antimuscarinic effects.
Metabolism
Oxybutynin undergoes extensive first-pass metabolism,
particularly by the cytochrome P450 isoenzyme
CYP3A4. One of the metabolites, N-desethyloxybutynin
is pharmacologically active.
Oxybutynin and its metabolites are excreted in the urine
and faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 1508-65-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,0 and 8 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1508-65:
(6*1)+(5*5)+(4*0)+(3*8)+(2*6)+(1*5)=72
72 % 10 = 2
So 1508-65-2 is a valid CAS Registry Number.
InChI:InChI=1/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
1508-65-2Relevant articles and documents
POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE
-
Paragraph 0152-0154, (2021/11/13)
Polymorphic forms of (R)-oxybutynin HC1, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HC1 for Obstructive Sleep Apnea (OS A) treatment are also disclosed.
SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES
-
Page/Page column 53-54, (2009/10/06)
Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
QUATERNARY AMMONIUM COMPOUNDS
-
Page 8, (2008/06/13)
The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
